High purity 99% factory price in stock Liraglutide CAS NO.204656-20-2
- FOB Price: USD: 25.00-800.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
Medicine Grade(1-99)KilogramMedicine Grade(100-1000)Kilogram
- Product Details
Keywords
- Liraglutide
- High purity 99%
- factory supply
Quick Details
- ProName: High purity 99% factory price in stock...
- CasNo: 204656-20-2
- Molecular Formula: C172h265n43o51
- Appearance: White powder
- Application: Victoza is FDA-approved for type 2 dia...
- DeliveryTime: in 7 days afte your payment ( in stock...
- PackAge: 1kg/bag ;5kg/drum:25KG/drum
- Port: any port in China
- ProductionCapacity: 20 Metric Ton/Month
- Purity: 99% up
- Storage: in low tempreture
- Transportation: in low tempreture
- LimitNum: 1 Kilogram
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Why choose us
1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin
Details
Product Information
Product Name | Liraglutide |
Appearance | White or white crystalline powder |
Assay | 99%min |
CAS | 204656-20-2 |
Dosage Form | Raw materials Orlista t powder |
Storage Temperature | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. |
Usage
Victoza is FDA-approved for type 2 diabetes mellitus (DM) and prophylaxis for disorder of cardiovascular system as a result of type 2 diabetes. Its dosing involves titration to reduce gastrointestinal symptoms, such as nausea, diarrhea, and vomiting: initiate 0.6 mg daily subcutaneous injection for 1 week; increase to maintenance dose of 1.2 mg daily; and increase to 1.8 mg daily, as needed.
Liraglutide is also FDA-approved as Saxenda for obesity with a body mass index of 30kg/m2< or 27kg/m2 with the presence of at least 1 weight-related comorbid condition. Saxenda is initiated at 0.6 mg subcutaneous daily injection for 1 week, with weekly increments of 0.6 mg per day, until the maintenance dosage of 3 mg once daily is reached.3 If the patient misses a dose of liraglutide injection for more than 3 days, re-initiation at 0.6 mg is recommended to mitigate gastrointestinal (GI) symptoms.
Function
1.It acts in a glucose-dependent manner, meaning it will stimulate insuli n secretion only when blood glucose levels are higher than normal, preventing ""overshoot"". Consequently, it shows negligible risk of hypoglycemia.
2.It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3.It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
4.It lowers blood triglyceride levels.